Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

New Therapeutic Options for the Management of the Hospitalized Patie…

28th Annual Heart Failure 2024: An Update on Therapy

U. Elkayam

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

High-Risk Cardiac Surgery and Pre-Op Optimization with Impella Base …

St. Louis Shock & Heart Failure Symposium 2022

J. Leidenfrost

Hemodynamic vs. Hemo-Metabolic Shock: Redefining Shock Profiles

The Cardiogenic Shock Working Group

N. Kapur

Contemporary Management of Cardiogenic Shock: Updates in 2022

Mount Sinai Advanced Innovations in Heart Failure

D. Baran

Use of MCS in Management of Acute Post-MI VSD

Houston Shock Symposium

D. Ramini

Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures

MUSC Cardiology

S. Litwin

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim